JP2009544734A - 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト - Google Patents

目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト Download PDF

Info

Publication number
JP2009544734A
JP2009544734A JP2009521989A JP2009521989A JP2009544734A JP 2009544734 A JP2009544734 A JP 2009544734A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009544734 A JP2009544734 A JP 2009544734A
Authority
JP
Japan
Prior art keywords
antagonist
alkyl
receptor
eye
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544734A5 (enExample
Inventor
デブラ エル． フレーノア，
アラン アール． シェパード，
イオク−ホウ パン，
Original Assignee
アルコン リサーチ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン リサーチ， リミテッド filed Critical アルコン リサーチ， リミテッド
Publication of JP2009544734A publication Critical patent/JP2009544734A/ja
Publication of JP2009544734A5 publication Critical patent/JP2009544734A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009521989A 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト Pending JP2009544734A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25
PCT/US2007/074351 WO2008014338A2 (en) 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2009544734A true JP2009544734A (ja) 2009-12-17
JP2009544734A5 JP2009544734A5 (enExample) 2011-03-10

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521989A Pending JP2009544734A (ja) 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト

Country Status (11)

Country Link
US (2) US20080025973A1 (enExample)
EP (1) EP2068856A2 (enExample)
JP (1) JP2009544734A (enExample)
KR (1) KR20090033886A (enExample)
CN (1) CN101505744A (enExample)
AU (1) AU2007279311A1 (enExample)
BR (1) BRPI0714593A2 (enExample)
CA (1) CA2657480A1 (enExample)
MX (1) MX2009000907A (enExample)
WO (1) WO2008014338A2 (enExample)
ZA (1) ZA200900316B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
CA2659599C (en) * 2006-08-08 2014-06-17 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US20110009453A1 (en) * 2008-03-17 2011-01-13 Donello John E s1p3 receptor inhibitors for treating inflammation
WO2010129553A1 (en) * 2009-05-05 2010-11-11 Allergan, Inc. S1p3 receptor inhibitors for treating conditions of the eye
RU2012105453A (ru) * 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
WO2011038446A1 (en) * 2009-09-30 2011-04-07 Stiefel Research Australia Pty Ltd Cosmetic foam
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019779A1 (en) * 1994-01-21 1995-07-27 Yale University Deltex proteins, nucleic acids, and antibodies, and related methods and compositions
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013811A1 (de) * 1993-11-17 1995-05-26 Byk Nederland Bv Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
US20060173046A1 (en) * 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
US7888527B2 (en) * 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
EP1935874A4 (en) * 2005-10-12 2010-10-13 Toa Eiyo Ltd S1P3 RECEPTOR ANTAGONIST
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019779A1 (en) * 1994-01-21 1995-07-27 Yale University Deltex proteins, nucleic acids, and antibodies, and related methods and compositions
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬

Also Published As

Publication number Publication date
ZA200900316B (en) 2010-05-26
CA2657480A1 (en) 2008-01-31
US20080025973A1 (en) 2008-01-31
US20100183629A1 (en) 2010-07-22
WO2008014338A3 (en) 2008-12-24
CN101505744A (zh) 2009-08-12
MX2009000907A (es) 2009-02-04
EP2068856A2 (en) 2009-06-17
WO2008014338A2 (en) 2008-01-31
BRPI0714593A2 (pt) 2013-05-07
AU2007279311A1 (en) 2008-01-31
KR20090033886A (ko) 2009-04-06

Similar Documents

Publication Publication Date Title
JP2009544734A (ja) 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US20120115870A1 (en) Control of intraocular pressure using alk5 modulation agents
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
RU2370267C2 (ru) Антагонисты cdk2 в качестве антагонистов короткой формы фактора транскрипции c-maf для лечения глаукомы
US20040213782A1 (en) Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
EP3747471A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
TW201927298A (zh) 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥
US20100247548A1 (en) Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
EP3668487A1 (en) Modulation of wnt5a to treat glaucoma
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
WO2014138018A1 (en) Preservative free bimatoprost and timolol solutions
Mokbel et al. Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
US20210363247A1 (en) Novel Treatments of Glaucoma
JP7429500B2 (ja) 角膜上皮障害治療剤
KR20080111092A (ko) 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제
Virani et al. An Update on Pharmacotherapy of Glaucoma
WO2020166679A1 (ja) 眼圧下降用医薬組成物
JP2004189735A (ja) Ｌｉｍキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120723

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121129